TOLREMO therapeutics
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
This person is not in any teams
This person is not in any offices
TOLREMO therapeutics
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.